Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Adv Exp Med Biol ; 1352: 195-210, 2021.
Article in English | MEDLINE | ID: covidwho-1669704

ABSTRACT

INTRODUCTION: Emerging data have demonstrated increased mortality of COVID-19 patients suffering from comorbid conditions such as Type II diabetes, hypertension, and cardiovascular diseases. Underlying risk in all these patients is an increase in bodyweight or obesity. The adverse health effects of obesity and how these factors enhance the risk of mortality in COVID-19 patients is still unexplored. OBJECTIVE: The enhanced fat deposition might be a risk factor for increased mortality in COVID-19 patients. METHOD: We have reviewed and collected the information from online databases: Pubmed, Google scholar, Researchgate, to highlight the systematic link between obesity with associated risks in COVID-19. RESULT: We have reported the first study during the pandemic from France and New York, to a currently reported study in Mexico and found individuals with BMI ≥35 kg/m2 or >40 kg/m2 have greater risk of developing critical illness due to COVID-19, thereby increasing mortality. CONCLUSION: Our study suggests obesity in childhood, adolescence, and adulthood can be considered a profound risk factor for greater susceptibility and severity of COVID-19 and is associated with nutritional, lifestyle, cardiac, respiratory, renal, and immunological alterations, which may potentiate the complications of SARS-CoV-2 infection. Further suggesting to check on BMI during this pandemic situation.


Subject(s)
COVID-19 , Obesity/complications , COVID-19/complications , COVID-19/mortality , Humans , Risk Factors , SARS-CoV-2
2.
J Environ Pathol Toxicol Oncol ; 40(1): 29-42, 2021.
Article in English | MEDLINE | ID: covidwho-1090492

ABSTRACT

In early December 2019, a novel coronavirus disease 2019 (COVID-19), the global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) commenced in Wuhan, China, and WHO declared the outbreak a pandemic and Public Health Emergency of International Concern. An ample number of clinical trials with multiple drugs is underway to overcome the current perilous condition. Still, the situation is alarming with no therapeutic measure in our hand at present. Keeping the present scenario in mind, this review comprises the research, clinical knowledge, and repurposed herbals with regard to COVID-19. Preventive measures such as yoga, nasal breathing, and herbal administration could also provide protection and beneficial effects against coronavirus. Innumerable clinical trials are ongoing to manage COVID-19 and the drugs were selected on the basis of life cycle of coronavirus. The selection of herbals was done on the basis of the previous reported pharmacological activities and docking study. The results concluded that garlic, liquorice, and Ashwagandha have a potential against SARS-CoV-2, which was further proved via a docking study and their reported biological functions. The very well-known fact "prevention is always better than cure" is applied to overcome with coronavirus infection. It is expected that following the preventive measures could impede or lessen the adverse effect of SARS-CoV-2.


Subject(s)
COVID-19/prevention & control , Phytotherapy , SARS-CoV-2 , Humans , Life Cycle Stages , Nitric Oxide/therapeutic use , Plants, Medicinal , SARS-CoV-2/chemistry , Yoga , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL